台股 » 個股 » 生展 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

生展

(8279)
  • 股價
    153.0
  • 漲跌
    ▲0.5
  • 漲幅
    +0.33%
  • 成交量
    2
  • 產業
    上櫃 生技醫療類股▼0.28%
  • 68人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
生展 (8279)籌碼相關-台中銀 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

台中銀 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2024/04/0900.001156.00160.00-110-9.80%
2024/03/2500.001161.50161.00-110-9.23%
2024/03/151156.5000.00156.501109.60%
2023/05/051184.0000.00182.001581.71%
2022/08/1000.000.1146.50146.00-0.156-0.13%
2022/06/100.1137.1900.00133.000.1410.16%
2022/01/200123.0000.00128.000450.02%
2021/04/0800.003118.00117.50-354-5.47%
2020/11/2700.000.4105.00112.50-0.440-1.02%
2020/08/313128.5000.00125.0031262.38%
2020/08/1100.009126.78126.00-997-9.20%
2020/07/104115.0000.00112.504695.76%
2020/06/0800.004116.50117.00-474-5.37%
2020/05/2800.001108.50109.00-192-1.08%
2020/05/113108.671110.00109.502952.10%
2020/05/081107.0000.00104.001931.07%
2020/04/23194.60193.8094.600930.00%
2020/04/22192.1000.0093.901931.07%
2019/12/2600.002120.00118.50-268-2.92%
2019/12/201118.5000.00118.001681.46%
2019/12/045118.0000.00117.005687.32%
2019/11/202113.5000.00116.002613.27%
2018/12/2500.00196.6096.60-134-2.88%
2018/12/241100.0000.0099.401352.84%
2018/08/1700.001103.50103.00-180-1.25%
2018/08/161101.5000.00101.001801.24%
2018/04/2300.002180.00172.00-2364-0.55%
2018/04/202169.2500.00173.0023420.58%
2018/04/111158.501157.50158.0003330.00%
2018/04/0200.002156.00160.50-2297-0.67%
2018/03/1300.001134.50134.50-1287-0.35%
2018/03/1200.001134.50133.50-1290-0.34%
2018/03/091137.0000.00136.5012920.34%
2018/03/0800.001142.00137.00-1293-0.34%
2018/03/071142.0000.00140.5012920.34%
2018/03/061139.0000.00139.5012970.34%
2018/02/262132.7500.00135.5023140.64%
2018/02/081162.501159.00155.5002930.00%
2018/02/071168.001165.00165.0002980.00%
2018/01/3100.001181.00181.00-1322-0.31%
2018/01/301176.5000.00177.0013240.31%
2018/01/2500.001176.50175.50-1317-0.32%
2018/01/231174.005173.00173.50-4314-1.27%
2018/01/165169.4000.00168.0052941.70%
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
〈聯合再生展望〉洪傳獻:TOPCon技術明年成主流 獲利表現佳Anue鉅亨-2023/10/16
生展 相關文章